1. Home
  2. GLW vs AMGN Comparison

GLW vs AMGN Comparison

Compare GLW & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corning Incorporated

GLW

Corning Incorporated

N/A

Current Price

$156.12

Market Cap

190.2B

Sector

Industrials

ML Signal

N/A

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$371.50

Market Cap

198.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GLW
AMGN
Founded
1851
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.2B
198.6B
IPO Year
2008
2002

Fundamental Metrics

Financial Performance
Metric
GLW
AMGN
Price
$156.12
$371.50
Analyst Decision
Buy
Hold
Analyst Count
12
19
Target Price
$146.91
$351.05
AVG Volume (30 Days)
12.9M
2.4M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
0.74%
2.98%
EPS Growth
215.52
88.23
EPS
0.43
3.34
Revenue
$15,629,000,000.00
$25,424,000,000.00
Revenue This Year
$20.74
$5.00
Revenue Next Year
$12.80
$2.45
P/E Ratio
$358.15
$109.60
Revenue Growth
19.14
8.83
52 Week Low
$54.89
$269.77
52 Week High
$271.78
$391.29

Technical Indicators

Market Signals
Indicator
GLW
AMGN
Relative Strength Index (RSI) 38.48 51.39
Support Level $153.33 $357.67
Resistance Level $156.17 $380.17
Average True Range (ATR) 10.15 8.25
MACD -4.87 -0.86
Stochastic Oscillator 13.49 26.66

Price Performance

Historical Comparison
GLW
AMGN

About GLW Corning Incorporated

Corning is a provider of glass, ceramics, and optical fiber across six distinct end markets. Corning's largest segments by revenue are display glass for TVs and optical fiber for telecom networks and data centers. It also provides cover glass for smartphones as well as filters and substrates and glass for cars, produces pharmaceutical glass, and produces polysilicon for solar panels. Corning is a US producer and is vertically integrated across its products and markets.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: